Use of immunomodulatory therapy as part of comprehensive treatment of non-severe community-acquired pneumonia and its long-term results.
IL-6
TNF
azoximer bromide
bacterial lysate
non-severe community-acquired pneumonia
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
10
2022
accepted:
13
06
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
This study investigates the efficiency of two different types of immunomodulators for the treatment of non-severe community-acquired pneumonia (CAP) and assesses their long-term effects. The study included 55 patients with non-severe CAP. Group 1 (control) received only standard CAP therapy; the other two groups received immunomodulators simultaneously with the standard therapy: bacterial lysate for group 2 and azoximer bromide (AzB) for group 3. TNF and IL-6 concentrations were determined on the day of hospitalization as well as on days 13 and 60 of follow-up. For 2 years, we monitored the incidence of low respiratory tract infections (LRTIs) in the same patients with CAP ( The overall duration of all symptoms was lower in the immunomodulator groups compared with the control group. During treatment, TNF and IL-6 concentrations decreased on days 13 and 60 in all patients; in patients who received immunomodulators, TNF and IL-6 were reliably lower than in control patients. IL-6 concentration decreased on day 60 in the bacterial lysate and AzB treatment groups and did not differ ( Inclusion of immunomodulators in the basic treatment of non-severe CAP reduces the duration of symptoms and is associated with improvement of the pro-inflammatory cytokine profile. In 2 years of follow-up, the long-term effects of the immunomodulatory therapy showed a statistically significant lower incidence of LRTIs in the AzB group only. However, given the small sample size of this study, further clinical studies are needed.
Sections du résumé
Background
UNASSIGNED
This study investigates the efficiency of two different types of immunomodulators for the treatment of non-severe community-acquired pneumonia (CAP) and assesses their long-term effects.
Methods
UNASSIGNED
The study included 55 patients with non-severe CAP. Group 1 (control) received only standard CAP therapy; the other two groups received immunomodulators simultaneously with the standard therapy: bacterial lysate for group 2 and azoximer bromide (AzB) for group 3. TNF and IL-6 concentrations were determined on the day of hospitalization as well as on days 13 and 60 of follow-up. For 2 years, we monitored the incidence of low respiratory tract infections (LRTIs) in the same patients with CAP (
Results
UNASSIGNED
The overall duration of all symptoms was lower in the immunomodulator groups compared with the control group. During treatment, TNF and IL-6 concentrations decreased on days 13 and 60 in all patients; in patients who received immunomodulators, TNF and IL-6 were reliably lower than in control patients. IL-6 concentration decreased on day 60 in the bacterial lysate and AzB treatment groups and did not differ (
Conclusion
UNASSIGNED
Inclusion of immunomodulators in the basic treatment of non-severe CAP reduces the duration of symptoms and is associated with improvement of the pro-inflammatory cytokine profile. In 2 years of follow-up, the long-term effects of the immunomodulatory therapy showed a statistically significant lower incidence of LRTIs in the AzB group only. However, given the small sample size of this study, further clinical studies are needed.
Identifiants
pubmed: 37602358
doi: 10.7573/dic.2022-10-5
pii: dic-2022-10-5
pmc: PMC10435266
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2023 Kostinov MP, Gainitdinova VV, Kazharova SV, Vlasenko AE, Polishchuk VB, Mashilov KV.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2023/07/dic.2022-10-5-COI.pdf
Références
Eur J Clin Microbiol Infect Dis. 2014 Jul;33(7):1065-79
pubmed: 24532008
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
Curr Infect Dis Rep. 2016 Mar;18(3):10
pubmed: 26874956
Lab Anim Res. 2015 Jun;31(2):78-85
pubmed: 26155202
Postgrad Med. 2010 Mar;122(2):130-41
pubmed: 20203464
Int Immunopharmacol. 2018 Jan;54:198-209
pubmed: 29154122
Clin Infect Dis. 2010 Jan 15;50(2):202-9
pubmed: 20014950
Clin Infect Dis. 2017 Nov 13;65(11):1806-1812
pubmed: 29020164
Eur Respir J. 2011 Jun;37(6):1431-8
pubmed: 20884746
Nutrients. 2020 May 06;12(5):
pubmed: 32384616